Caris Life Sciences reports Q3 EPS 8c, consensus (14c)

Reports Q3 revenue $216.8M, consensus $174.22M. “We delivered another record quarter for revenue and clinical volume, achieving positive net income and demonstrating the operating strength of our comprehensive, patient-first approach,” said David D. Halbert, CEO. “These results reflect the core strength of our business and our continued progress toward delivering the next generation of personalized solutions through our exciting pipeline in MRD and early detection.”